1Waites KB,Talkington DF.Mycoplasma pneumoniae and its role as a human pathogen[J].Clin Mierobiol Rev,2004,17(4):697-728.
2Chaudhry R,Varahney AK,Malhotra P.Adhesion proteins of Mycoplas ma pneumoniae[J].Front Biosci,2007,12:690-699.
3Yavlovich A,Tarshis M,Rottem S.Internalization and intracellular survival of Mycoplasma pneumoniae by non-phagocytic cells[J].FEMS Microbiol Lett,2004,233(2):241-246.
4Kannan TR,Provenzano D,Wright JR,et al.Identification and characterization of human surfactant protein A binding protein of Mycoplasma pneumoniae[J].Infect Immun,2005,73 (5):2828-2834.
5Kannan TR,Baseman JR.ADP-ribosylating and vacuolating eytotoxin of Mycoplasma pneumoniae represents unique virulence determinant among bacterial pathogens[J].Proc Nail Acad Sci USA,2006,103 (17):6724-6729.
6Kunnan TR,Provenzano D,Wright JR,et al.Identification and characterization of human surfactant protein A binging protein of Mycoplasma pneumoniae[J].Infect Immun,2005,73(5):2828-2834.
7Shimizu T,Kida Y,Kuwano K.A dipalmitoylated lipoprotein from Mycoplasma pneumoniae activates NF-kappa B through TLR1,TLR2 and TLR6[J].J Immunol,2005,175(7):4641-4646.
8Into T,Kiura K,Yasuda M.et al.Stimulation of human Tolllike receptor (TLR)2 and TLR6 with membrane lipoproteins of Mycoplasma fementans induces apoptotic cell death after NFkappa B activation[J].Cell Microbiol,2004.6(2):187-199.
9Stelmach I,Podsiodlowicz-Borzeka M,Grzelewski T,et al.Humoral and cellular immunity in children with Mycoplasma pneumoniae infection:a 1-year prospective study[J].Clin Diagn Lab Immunol,2005,12(10):1246-1250.
10Aurora AB,Baluk P,Zhang D,et al.Immune complex-dependent remodeling of the airway vasculature in response to achronic bacterial infection[J].J Immunol,2005,175(10):6319-6326.
